HSD17B14
gene geneOn this page
Also known as retSDR3SDR47C1
Summary
HSD17B14 (hydroxysteroid 17-beta dehydrogenase 14, HGNC:23238) is a protein-coding gene on chromosome 19q13.33, encoding L-fucose dehydrogenase (Q9BPX1). Catalyzes the NAD(+)-dependent oxidation of L-fucose, yielding L-fucono-1,5-lactone, which rapidly converts spontaneously to L-fucone-1,4-lactone.
17-beta-hydroxysteroid dehydrogenases, such as HSD17B14, are primarily involved in metabolism of steroids at the C17 position and also of other substrates, such as fatty acids, prostaglandins, and xenobiotics (Lukacik et al., 2007 [PubMed 17067289]).
Source: NCBI Gene 51171 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 52 total
- Druggable target: yes
- MANE Select transcript:
NM_016246
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:23238 |
| Approved symbol | HSD17B14 |
| Name | hydroxysteroid 17-beta dehydrogenase 14 |
| Location | 19q13.33 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | retSDR3, SDR47C1 |
| Ensembl gene | ENSG00000087076 |
| Ensembl biotype | protein_coding |
| OMIM | 612832 |
| Entrez | 51171 |
Gene structure
Transcript identifiers
Ensembl transcripts: 13 — 13 protein_coding
ENST00000263278, ENST00000595764, ENST00000596349, ENST00000599157, ENST00000867477, ENST00000867478, ENST00000867479, ENST00000867480, ENST00000867481, ENST00000867482, ENST00000867483, ENST00000931891, ENST00000931892
RefSeq mRNA: 1 — MANE Select: NM_016246
NM_016246
CCDS: CCDS12736
Canonical transcript exons
ENST00000263278 — 9 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000554872 | 48831668 | 48831759 |
| ENSE00000718241 | 48813456 | 48813552 |
| ENSE00000718247 | 48813663 | 48813730 |
| ENSE00000718253 | 48815037 | 48815141 |
| ENSE00000718264 | 48832666 | 48832732 |
| ENSE00000718268 | 48834276 | 48834358 |
| ENSE00000718274 | 48835805 | 48835843 |
| ENSE00001235120 | 48836324 | 48836491 |
| ENSE00003117535 | 48813018 | 48813348 |
Expression profiles
Bgee: expression breadth ubiquitous, 227 present calls, max score 94.48.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6333 / max 140.5108, expressed in 1311 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 181938 | 5.7418 | 1119 |
| 181936 | 1.5152 | 570 |
| 181937 | 1.0011 | 511 |
| 181939 | 0.3751 | 217 |
Top tissues by expression
280 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| mucosa of stomach | UBERON:0001199 | 94.48 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 94.22 | gold quality |
| right lobe of liver | UBERON:0001114 | 93.70 | gold quality |
| left ovary | UBERON:0002119 | 93.62 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 92.54 | gold quality |
| adrenal cortex | UBERON:0001235 | 92.22 | gold quality |
| left adrenal gland | UBERON:0001234 | 92.20 | gold quality |
| right adrenal gland | UBERON:0001233 | 92.11 | gold quality |
| nucleus accumbens | UBERON:0001882 | 91.85 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 91.24 | gold quality |
| right ovary | UBERON:0002118 | 91.21 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 91.16 | gold quality |
| caudate nucleus | UBERON:0001873 | 91.07 | gold quality |
| amygdala | UBERON:0001876 | 90.75 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 90.68 | gold quality |
| cerebellar cortex | UBERON:0002129 | 90.59 | gold quality |
| endocervix | UBERON:0000458 | 90.42 | gold quality |
| putamen | UBERON:0001874 | 89.98 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 89.89 | gold quality |
| body of uterus | UBERON:0009853 | 89.74 | gold quality |
| left uterine tube | UBERON:0001303 | 89.52 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 89.51 | gold quality |
| cingulate cortex | UBERON:0003027 | 89.45 | gold quality |
| adrenal gland | UBERON:0002369 | 89.34 | gold quality |
| right frontal lobe | UBERON:0002810 | 89.11 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 89.03 | gold quality |
| retina | UBERON:0000966 | 89.01 | gold quality |
| cerebellum | UBERON:0002037 | 89.00 | gold quality |
| adenohypophysis | UBERON:0002196 | 88.93 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 88.78 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-6701 | yes | 45.19 |
| E-MTAB-5061 | yes | 25.94 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
14 targeting HSD17B14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-378G | 99.71 | 64.90 | 1106 |
| HSA-MIR-5697 | 99.39 | 67.74 | 1249 |
| HSA-MIR-3064-5P | 99.26 | 66.13 | 1497 |
| HSA-MIR-3085-3P | 99.26 | 66.16 | 1490 |
| HSA-MIR-6504-5P | 99.26 | 65.95 | 1487 |
| HSA-MIR-4651 | 99.06 | 67.57 | 2002 |
| HSA-MIR-608 | 98.93 | 67.83 | 2013 |
| HSA-MIR-6829-5P | 98.86 | 65.12 | 1480 |
| HSA-MIR-6819-5P | 97.96 | 66.59 | 1071 |
| HSA-MIR-5007-5P | 97.95 | 64.71 | 614 |
| HSA-MIR-6737-5P | 97.75 | 66.54 | 1044 |
| HSA-MIR-296-5P | 97.61 | 64.02 | 851 |
| HSA-MIR-6812-5P | 97.56 | 65.39 | 1059 |
| HSA-MIR-874-5P | 96.93 | 63.92 | 1014 |
Literature-anchored findings (GeneRIF, showing 5)
- crystal structure of the DHRS10 apoenzyme exhibits secondary structure of the SDR (short-chain dehydrogenase/reductase) family (PMID:17067289)
- Results show that tumoural expression levels of 17betaHSD14 can predict the outcome of adjuvant tamoxifen treatment in terms of local recurrence-free survival in patients with lymph node-negative ER+ breast cancer. (PMID:22792371)
- Five new variants of HSD17B14 characterized by crystallography and enzyme kinetics. Tyr253’ from the adjacent monomer ties the two monomers together. Disulfide bridge formed by Cys255 and Cys255’ is not crucial for dimer stabilization. (PMID:30836176)
- Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. (PMID:34261756)
- Hydroxysteroid 17-beta dehydrogenase 14 (HSD17B14) is an L-fucose dehydrogenase, the initial enzyme of the L-fucose degradation pathway. (PMID:38944119)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | hsd17b14 | ENSDARG00000054842 |
| mus_musculus | Hsd17b14 | ENSMUSG00000030825 |
| rattus_norvegicus | Hsd17b14 | ENSRNOG00000020949 |
| caenorhabditis_elegans | WBGENE00014093 |
Paralogs (25): HSD17B6 (ENSG00000025423), RDH11 (ENSG00000072042), HSD17B10 (ENSG00000072506), DHRS9 (ENSG00000073737), HSD17B2 (ENSG00000086696), DHRS12 (ENSG00000102796), HSDL1 (ENSG00000103160), HSD17B1 (ENSG00000108786), RDH10 (ENSG00000121039), HSD17B3 (ENSG00000130948), HSD17B7 (ENSG00000132196), HSD17B4 (ENSG00000133835), RDH5 (ENSG00000135437), RDH16 (ENSG00000139547), RDH12 (ENSG00000139988), HSD17B12 (ENSG00000149084), BDH1 (ENSG00000161267), DHRS3 (ENSG00000162496), SDR9C7 (ENSG00000170426), HSD17B13 (ENSG00000170509), SDR16C5 (ENSG00000170786), HSD11B2 (ENSG00000176387), WWOX (ENSG00000186153), HSD17B11 (ENSG00000198189), HSD17B8 (ENSG00000204228)
Protein
Protein identifiers
L-fucose dehydrogenase — Q9BPX1 (reviewed: Q9BPX1)
Alternative names: 17-beta-hydroxysteroid dehydrogenase DHRS10, Dehydrogenase/reductase SDR family member 10, Retinal short-chain dehydrogenase/reductase retSDR3, Short chain dehydrogenase/reductase family 47C member 1
All UniProt accessions (5): Q9BPX1, A0A140VJH8, M0QY35, M0R147, M0R2R3
UniProt curated annotations — full annotation on UniProt →
Function. Catalyzes the NAD(+)-dependent oxidation of L-fucose, yielding L-fucono-1,5-lactone, which rapidly converts spontaneously to L-fucone-1,4-lactone. Can also act on D-arabinose and L-galactose, with lower catalytic efficiency. Does not use NADPH. May be the initial enzyme of the L-fucose degradation pathway in mammals.
Subunit / interactions. Homotetramer.
Subcellular location. Cytoplasm.
Tissue specificity. Highly expressed in brain, placenta, liver and kidney.
Pathway. Carbohydrate degradation; L-fucose degradation.
Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.
RefSeq proteins (1): NP_057330* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002347 | SDR_fam | Family |
| IPR020904 | Sc_DH/Rdtase_CS | Conserved_site |
| IPR036291 | NAD(P)-bd_dom_sf | Homologous_superfamily |
Pfam: PF13561
Enzyme classification (BRENDA):
- EC 1.1.1.62 — 17beta-estradiol 17-dehydrogenase (BRENDA: 20 organisms, 283 substrates, 790 inhibitors, 95 Km, 44 kcat entries)
Substrate kinetics (BRENDA)
32 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.
| Substrate | Km (mM) | Measurements |
|---|---|---|
| ESTRADIOL-17BETA | 0.0008–0.025 | 14 |
| ESTRONE | — | 10 |
| NADP+ | 0.0001–9 | 9 |
| 17BETA-ESTRADIOL | 0.0006–0.082 | 7 |
| NADPH | 0.0003–0.16 | 7 |
| ESTRADIOL | 0.0036–0.118 | 6 |
| TESTOSTERONE | 0.0071–0.263 | 4 |
| DEHYDROEPIANDROSTERONE | 0.0172–0.0598 | 3 |
| 5-ANDROSTENE-3BETA,17BETA-DIOL | 0.0066–0.0078 | 2 |
| 5ALPHA-DIHYDROTESTOSTERONE | 0.0067–0.118 | 2 |
| 5BETA-PREGNAN-20ALPHA-OL-3-ONE | 0.0011–0.0033 | 2 |
| DIHYDROTESTOSTERONE | 0.0043–0.033 | 2 |
| NAD+ | 0.357–0.5 | 2 |
| (S)-INDAN-1-OL | 0.508 | 1 |
| 1-METHYL-6-DEHYDROESTRADIOL | 0.0085 | 1 |
Catalyzed reactions (Rhea), 3 shown:
- L-fucose + NAD(+) = L-fucono-1,5-lactone + NADH + H(+) (RHEA:81515)
- D-arabinose + NAD(+) = D-arabinono-1,5-lactone + NADH + H(+) (RHEA:81519)
- L-galactose + NAD(+) = L-galactono-1,5-lactone + NADH + H(+) (RHEA:81523)
UniProt features (45 total): binding site 12, helix 12, strand 8, mutagenesis site 5, turn 3, sequence variant 2, chain 1, active site 1, sequence conflict 1
Structure
Experimental structures (PDB)
31 structures, top 30 by resolution.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 6H0M | X-RAY DIFFRACTION | 1.25 |
| 5O6X | X-RAY DIFFRACTION | 1.35 |
| 6G4L | X-RAY DIFFRACTION | 1.44 |
| 5O6O | X-RAY DIFFRACTION | 1.45 |
| 5O43 | X-RAY DIFFRACTION | 1.5 |
| 6ZR6 | X-RAY DIFFRACTION | 1.5 |
| 5EN4 | X-RAY DIFFRACTION | 1.52 |
| 5ICS | X-RAY DIFFRACTION | 1.52 |
| 5O6Z | X-RAY DIFFRACTION | 1.57 |
| 5O7C | X-RAY DIFFRACTION | 1.6 |
| 6GTB | X-RAY DIFFRACTION | 1.62 |
| 6FFB | X-RAY DIFFRACTION | 1.65 |
| 5ICM | X-RAY DIFFRACTION | 1.68 |
| 6HNO | X-RAY DIFFRACTION | 1.68 |
| 6QCK | X-RAY DIFFRACTION | 1.68 |
| 6ZRA | X-RAY DIFFRACTION | 1.73 |
| 5L7W | X-RAY DIFFRACTION | 1.76 |
| 5O42 | X-RAY DIFFRACTION | 1.76 |
| 5JSF | X-RAY DIFFRACTION | 1.84 |
| 6ZDE | X-RAY DIFFRACTION | 1.87 |
| 5O72 | X-RAY DIFFRACTION | 1.91 |
| 5L7Y | X-RAY DIFFRACTION | 1.91 |
| 6ZT2 | X-RAY DIFFRACTION | 1.95 |
| 5L7T | X-RAY DIFFRACTION | 1.98 |
| 5JS6 | X-RAY DIFFRACTION | 2 |
| 5HS6 | X-RAY DIFFRACTION | 2.02 |
| 6GBT | X-RAY DIFFRACTION | 2.1 |
| 6ZDI | X-RAY DIFFRACTION | 2.13 |
| 6GTU | X-RAY DIFFRACTION | 2.25 |
| 1YDE | X-RAY DIFFRACTION | 2.4 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9BPX1-F1 | 96.67 | 0.94 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1): 154 (proton acceptor)
Ligand- & substrate-binding residues (12): 158; 187; 189; 191; 19; 21; 40; 41; 62; 63; 89; 154
Mutagenesis-validated functional residues (5):
| Position | Phenotype |
|---|---|
| 93 | increases kcat for androst-5-en-3beta,17beta-diol and 17beta-estradioll. |
| 148 | the catalytic efficiency (kcat/km) is 30-fold increase for 17beta-estradiol and 11-fold for androst-5-en-3beta,17beta-di |
| 158 | lacks of activity of testosterone 17-beta-dehydrogenase (nadp+) and estradiol 17-beta-dehydrogenase [nad(p)+] activities |
| 253 | lacks of activity of testosterone 17-beta-dehydrogenase (nadp+) and estradiol 17-beta-dehydrogenase [nad(p)+] activities |
| 255 | does not affect kcat for androst-5-en-3beta,17beta-diol and 17beta-estradiol. |
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-193144 | Estrogen biosynthesis |
MSigDB gene sets: 88 (showing top):
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_MONOSACCHARIDE_CATABOLIC_PROCESS, CHANDRAN_METASTASIS_DN, KOYAMA_SEMA3B_TARGETS_UP, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, NELSON_RESPONSE_TO_ANDROGEN_UP, GOBP_LIPID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, AACTTT_UNKNOWN, GOBP_CARBOHYDRATE_CATABOLIC_PROCESS, GOBP_FUCOSE_METABOLIC_PROCESS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS, GOBP_MONOSACCHARIDE_METABOLIC_PROCESS, GOBP_STEROID_METABOLIC_PROCESS, MIKKELSEN_IPS_LCP_WITH_H3K4ME3
GO Biological Process (4): steroid metabolic process (GO:0008202), L-fucose catabolic process (GO:0042355), fucose metabolic process (GO:0006004), lipid metabolic process (GO:0006629)
GO Molecular Function (5): identical protein binding (GO:0042802), D-threo-aldose 1-dehydrogenase activity (GO:0047834), estradiol 17-beta-dehydrogenase [NAD(P)+] activity (GO:0004303), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)
GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Metabolism of steroid hormones | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| lipid metabolic process | 1 |
| hexose catabolic process | 1 |
| L-fucose metabolic process | 1 |
| hexose metabolic process | 1 |
| primary metabolic process | 1 |
| protein binding | 1 |
| oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1 |
| steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1 |
| binding | 1 |
| catalytic activity | 1 |
| cytoplasm | 1 |
| intracellular anatomical structure | 1 |
Protein interactions and networks
STRING
3281 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| HSD17B14 | HSD17B1 | P14061 | 599 |
| HSD17B14 | HSD17B3 | P37058 | 583 |
| HSD17B14 | HSD17B12 | Q53GQ0 | 538 |
| HSD17B14 | FRRS1 | Q6ZNA5 | 507 |
| HSD17B14 | AKR1C3 | P42330 | 445 |
| HSD17B14 | HSD17B4 | P51659 | 411 |
| HSD17B14 | TNFSF12 | O43508 | 400 |
| HSD17B14 | ITPRID2 | P28290 | 397 |
| HSD17B14 | TNFSF11 | O14788 | 394 |
| HSD17B14 | MIOX | Q9UGB7 | 391 |
| HSD17B14 | PLEKHA4 | Q9H4M7 | 388 |
| HSD17B14 | DHDH | Q9UQ10 | 387 |
| HSD17B14 | GPER1 | Q99527 | 387 |
| HSD17B14 | HSD3B1 | P14060 | 377 |
| HSD17B14 | ECHDC1 | Q9NTX5 | 366 |
IntAct
149 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| NTAQ1 | HSD17B14 | psi-mi:“MI:0915”(physical association) | 0.920 |
| HSD17B14 | NTAQ1 | psi-mi:“MI:0915”(physical association) | 0.920 |
| HSD17B14 | CA8 | psi-mi:“MI:0915”(physical association) | 0.890 |
| CA8 | HSD17B14 | psi-mi:“MI:0915”(physical association) | 0.890 |
| HSD17B14 | HSD17B14 | psi-mi:“MI:0915”(physical association) | 0.860 |
| HSD17B14 | CDKN2D | psi-mi:“MI:0915”(physical association) | 0.790 |
BioGRID (75): HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), HSD17B14 (Two-hybrid), WDYHV1 (Two-hybrid), TBC1D22B (Two-hybrid), LINC00152 (Two-hybrid), SREK1IP1 (Two-hybrid), MIR4435-1HG (Two-hybrid), HSD17B14 (Two-hybrid)
ESM2 similar proteins: A0A097ZPC9, A0A0F7U1Z1, A0A0H3KNE7, A0A1E1FFP5, A0A1L9WLH9, A0A1Y0BRF8, A0A2I1BSW8, A0A2I1C3T5, A0A3G9HAL8, A0A4P8DJW8, A0A6S6QNE4, A0A7T8F1N2, A0A8D5M6H6, A5W4G5, A7AZH2, B5Z114, B6HV34, C8WGQ3, C8WJW0, H1VN83, M1W270, O52384, O69264, P08088, P08694, P0AET8, P0AET9, P0C622, P13859, P19871, P23102, P47227, P50206, P55435, P72220, P9WEQ5, P9WGQ4, P9WGQ5, P9WGQ8, P9WGQ9
Diamond homologs: A0A075TRB3, A0A1L5BU05, A0A2U8U2K8, A0A8F5XX49, A1CFM1, A4FUZ6, C1DMX5, D4Z260, D7PI11, E0D7H5, E9Q3D4, F4JZN6, H1VN83, H9XP47, O24990, O31680, P06235, P07914, P08694, P0A2D1, P0A2D2, P0AG84, P0AG85, P10528, P19337, P39333, P39483, P39484, P39485, P39640, P40398, P42556, P54616, P54795, P9WGQ4, P9WGQ5, Q05069, Q0WRJ2, Q1NEJ0, Q2FZQ3
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
52 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 36 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1129 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:48813344:AGTGG:A | acceptor_gain | 1.0000 |
| 19:48813345:GTGG:G | acceptor_gain | 1.0000 |
| 19:48813346:TGG:T | acceptor_gain | 1.0000 |
| 19:48813347:GG:G | acceptor_gain | 1.0000 |
| 19:48813348:GC:G | acceptor_loss | 1.0000 |
| 19:48813349:C:CC | acceptor_gain | 1.0000 |
| 19:48813349:CTGGG:C | acceptor_loss | 1.0000 |
| 19:48813550:ATA:A | acceptor_gain | 1.0000 |
| 19:48813551:TA:T | acceptor_gain | 1.0000 |
| 19:48813553:C:CC | acceptor_gain | 1.0000 |
| 19:48813656:AGCTC:A | donor_loss | 1.0000 |
| 19:48813657:GCTCA:G | donor_loss | 1.0000 |
| 19:48813658:CTCA:C | donor_loss | 1.0000 |
| 19:48813659:TCA:T | donor_loss | 1.0000 |
| 19:48813660:CACCA:C | donor_loss | 1.0000 |
| 19:48813661:A:AC | donor_gain | 1.0000 |
| 19:48813661:A:AG | donor_loss | 1.0000 |
| 19:48813662:C:CA | donor_loss | 1.0000 |
| 19:48813662:C:CC | donor_gain | 1.0000 |
| 19:48813671:TCGGA:T | donor_gain | 1.0000 |
| 19:48813672:CGGAC:C | donor_gain | 1.0000 |
| 19:48813727:CCCC:C | acceptor_gain | 1.0000 |
| 19:48813728:CCC:C | acceptor_gain | 1.0000 |
| 19:48813728:CCCC:C | acceptor_gain | 1.0000 |
| 19:48813729:CC:C | acceptor_gain | 1.0000 |
| 19:48813729:CCC:C | acceptor_gain | 1.0000 |
| 19:48813729:CCCT:C | acceptor_loss | 1.0000 |
| 19:48813730:CC:C | acceptor_gain | 1.0000 |
| 19:48813731:C:CC | acceptor_gain | 1.0000 |
| 19:48813731:C:CG | acceptor_loss | 1.0000 |
AlphaMissense
1714 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:48813665:G:C | N180K | 0.992 |
| 19:48813665:G:T | N180K | 0.992 |
| 19:48815037:C:A | K158N | 0.990 |
| 19:48815037:C:G | K158N | 0.990 |
| 19:48815088:G:C | S141R | 0.988 |
| 19:48815088:G:T | S141R | 0.988 |
| 19:48815090:T:G | S141R | 0.988 |
| 19:48832679:G:C | N88K | 0.986 |
| 19:48832679:G:T | N88K | 0.986 |
| 19:48813550:A:T | I182N | 0.985 |
| 19:48815097:G:C | N138K | 0.985 |
| 19:48815097:G:T | N138K | 0.985 |
| 19:48813550:A:C | I182S | 0.977 |
| 19:48813550:A:G | I182T | 0.977 |
| 19:48813298:G:C | F230L | 0.976 |
| 19:48813298:G:T | F230L | 0.976 |
| 19:48813300:A:G | F230L | 0.976 |
| 19:48813552:A:C | C181W | 0.976 |
| 19:48813675:A:T | V177D | 0.974 |
| 19:48813711:G:A | T165I | 0.973 |
| 19:48815044:G:T | A156D | 0.973 |
| 19:48815089:C:A | S141I | 0.973 |
| 19:48813315:C:A | G225W | 0.972 |
| 19:48815051:A:G | Y154H | 0.972 |
| 19:48813277:G:C | F237L | 0.971 |
| 19:48813277:G:T | F237L | 0.971 |
| 19:48813279:A:G | F237L | 0.971 |
| 19:48813707:T:A | K166N | 0.971 |
| 19:48813707:T:G | K166N | 0.971 |
| 19:48813548:A:G | S183P | 0.968 |
dbSNP variants (sampled 300 via entrez): RS1000041482 (19:48817233 A>G), RS1000051435 (19:48821165 A>T), RS1000109350 (19:48828197 C>T), RS1000413451 (19:48827262 C>T), RS1000431597 (19:48823034 G>A), RS1000755666 (19:48838285 A>C), RS1000794439 (19:48821337 A>G), RS1001102979 (19:48837840 G>A), RS1001325871 (19:48832442 C>T), RS1001350273 (19:48814953 G>A,C), RS1001706161 (19:48821924 T>C), RS1002017154 (19:48814741 G>A), RS1002123819 (19:48837322 A>C,G), RS1002150582 (19:48820977 C>G), RS1002241311 (19:48837689 C>T)
Disease associations
OMIM: gene MIM:612832 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004523_4 | Resting metabolic rate | 3.000000e-06 |
| GCST006585_2580 | Blood protein levels | 3.000000e-08 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0008004 | resting metabolic rate measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL3712868 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
ChEMBL bioactivities
49 potent at pChembl≥5 of 49 total, top 47 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).
PubChem BioAssay actives
49 with measured affinity, of 155 total; 47 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.
| Compound | Assay | Type | Value | Unit |
|---|---|---|---|---|
| 2-fluoro-3-[6-[1-(4-fluoro-3-hydroxyphenyl)ethenyl]-2-pyridinyl]phenol | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0015 | uM |
| (4-fluoro-3-hydroxyphenyl)-(6-methylquinolin-2-yl)methanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0060 | uM |
| (4-fluoro-3-hydroxyphenyl)-naphthalen-2-ylmethanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0060 | uM |
| (4-fluoro-3-hydroxyphenyl)-[7-(4-hydroxy-3-methylphenyl)quinolin-2-yl]methanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0060 | uM |
| [6-[3-(dimethylamino)phenyl]-2-pyridinyl]-(4-fluoro-3-hydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0070 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(3-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0070 | uM |
| [6-(3,4-dihydroxyphenyl)-2-pyridinyl]-(4-fluoro-3-hydroxyphenyl)methanone | 1313658: Inhibition of human 17-beta-HSD14 using estradiol as substrate after 15 mins by fluorimetric assay | ki | 0.0070 | uM |
| (2,4-difluoro-3-hydroxyphenyl)-[6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0090 | uM |
| 2-(4-fluoro-3-hydroxybenzoyl)quinoline-7-carbonitrile | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0090 | uM |
| [5,6-bis(4-hydroxy-3-methylphenyl)-2-pyridinyl]-(4-fluoro-3-hydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0090 | uM |
| (4-fluoro-3-hydroxyphenyl)-[7-(2H-tetrazol-5-yl)quinolin-2-yl]methanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0100 | uM |
| (4-fluoro-2,3-dihydroxyphenyl)-[6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0110 | uM |
| (4-fluoro-3-hydroxyphenyl)-quinolin-2-ylmethanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0120 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0130 | uM |
| (4-fluoro-3-hydroxyphenyl)-[5-(2-fluoro-3-hydroxyphenyl)-6-(4-hydroxy-3-methylphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0150 | uM |
| (4-fluoro-3-hydroxyphenyl)-[5-(3-fluoro-4-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0170 | uM |
| (2,3-dihydroxyphenyl)-[3-(2-fluoro-3-hydroxyphenyl)phenyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0210 | uM |
| 2-[[2-(4-fluoro-3-hydroxybenzoyl)quinolin-7-yl]amino]acetic acid | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0230 | uM |
| (4-fluoro-3-hydroxyphenyl)-[5-(4-hydroxy-3-methylphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0240 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(4-hydroxy-3-methylphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0260 | uM |
| (7-aminoquinolin-2-yl)-(4-fluoro-3-hydroxyphenyl)methanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0340 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(3-fluoro-4-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0360 | uM |
| 2-fluoro-3-[6-(4-fluoro-3-hydroxy-N-methylanilino)-2-pyridinyl]phenol | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0420 | uM |
| (2,3-dihydroxyphenyl)-[6-(3-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0440 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(3-hydroxy-4-methylphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0470 | uM |
| 2-fluoro-3-[6-(4-fluoro-3-hydroxyanilino)-2-pyridinyl]phenol | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0470 | uM |
| (4-fluoro-3-hydroxyphenyl)-(6-phenoxy-2-pyridinyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0500 | uM |
| 2-fluoro-3-[6-(4-fluoro-3-hydroxyphenoxy)-2-pyridinyl]phenol | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.0580 | uM |
| (4-fluoro-3-hydroxyphenyl)-(6-phenyl-2-pyridinyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0630 | uM |
| (2,3-dihydroxyphenyl)-[6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0640 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(2-fluoro-3-hydroxyphenyl)-4-(hydroxymethyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0860 | uM |
| (4-fluoro-3-hydroxyphenyl)-(6-thiophen-3-yl-2-pyridinyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.0970 | uM |
| (4-fluoro-3-hydroxyphenyl)-(6-hydroxyquinolin-2-yl)methanone | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.1190 | uM |
| 3-[(Z)-[6-(2-fluoro-3-hydroxyphenyl)-1-hydroxy-2-pyridinylidene]-hydroxymethyl]cyclohexa-3,5-diene-1,2-dione | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.1320 | uM |
| [6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]-(2-hydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.1350 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(4-methylpiperazin-1-yl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.1900 | uM |
| [6-(3-chloro-4-fluorophenyl)-2-pyridinyl]-(4-fluoro-3-hydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.1900 | uM |
| (4-fluoro-3-hydroxyphenyl)-[6-(4-fluorophenyl)-2-pyridinyl]methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.2210 | uM |
| [6-(4-hydroxy-3-methylphenyl)-2-pyridinyl]-(3-hydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.2450 | uM |
| 6-(2-fluoro-3-hydroxyphenyl)-N-(4-fluoro-3-hydroxyphenyl)pyridine-2-carboxamide | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.3360 | uM |
| [6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]-(2,3,4-trihydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.4050 | uM |
| (4-fluoro-3-hydroxyphenyl)-(6-piperidin-1-yl-2-pyridinyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.4070 | uM |
| [6-(3-fluoro-4-hydroxyphenyl)-2-pyridinyl]-(3-hydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.4670 | uM |
| 4-fluoro-N-[6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]-3-hydroxybenzamide | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 0.6860 | uM |
| [6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]-(2,3,6-trihydroxyphenyl)methanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 0.7960 | uM |
| (4-fluoro-3-hydroxyphenyl)-pyridin-2-ylmethanone | 1322642: Inhibition of N-terminal 6His-tagged human human HSD17B14 expressed in Escherichia coli BL21 (DE3) pLysS using E2 substrate and NAD+ incubated for 2 hrs using purified enzyme by fluorimetric assay | ki | 1.5410 | uM |
| 4-fluoro-N-[6-(2-fluoro-3-hydroxyphenyl)-2-pyridinyl]-3-hydroxy-N-methylbenzamide | 1360338: Binding affinity to recombinant 17beta-HSD14 (unknown origin) expressed in Escherichia coli BL21 pLysS strain using E2 as substrate in presence of NAD measured continuously for 15 mins by fluorimetric method | ki | 2.0300 | uM |
CTD chemical–gene interactions
41 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression, increases expression | 3 |
| Benzo(a)pyrene | affects methylation | 2 |
| Cisplatin | affects expression, affects cotreatment, increases expression | 2 |
| Valproic Acid | decreases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| sotorasib | decreases expression, affects cotreatment | 1 |
| trichostatin A | decreases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | increases expression | 1 |
| sodium arsenite | increases expression | 1 |
| benzo(e)pyrene | increases methylation | 1 |
| aflatoxin B2 | increases methylation | 1 |
| avobenzone | increases expression | 1 |
| fipronil | affects cotreatment, increases expression | 1 |
| abrine | increases expression | 1 |
| jinfukang | affects cotreatment, increases expression | 1 |
| trametinib | affects cotreatment, decreases expression | 1 |
| NVP-BKM120 | affects cotreatment, decreases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Decitabine | affects expression | 1 |
| Sunitinib | increases expression | 1 |
| Glyphosate | increases expression | 1 |
| DEET | affects cotreatment, increases expression | 1 |
| Estradiol | decreases expression | 1 |
| Fluoxetine | increases expression | 1 |
| Hydrogen Peroxide | affects cotreatment, decreases expression | 1 |
| Methapyrilene | increases methylation | 1 |
| NAD | affects binding, increases activity | 1 |
| Niclosamide | increases expression | 1 |
| Rotenone | increases expression | 1 |
| Silicon Dioxide | increases expression | 1 |
ChEMBL screening assays
13 unique, capped per target: 13 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL3830811 | Binding | Inhibition of human 17-beta-HSD14 using estradiol as substrate after 15 mins by fluorimetric assay | New Insights into Human 17β-Hydroxysteroid Dehydrogenase Type 14: First Crystal Structures in Complex with a Steroidal Ligand and with a Potent Nonsteroidal Inhibitor. — J Med Chem |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.